Study design

observatiol study

Study time

2017.3-2020.4

Country

Netherlands

Object

patients who underwent RARP and extended pelvic lymph node dissection (ePLND) for unfavourable intermediate‐ or high‐risk PCa.

Inclusion criteria

Patients were excluded from the alyses if they underwent neoadjuvant testosterone‐lowering treatment, if they did not have any (biochemical) follow‐up after surgery, did not undergo ePLND or staging with PSMA PET imaging or if they had evidence of distant metastases on staging PSMA PET.

Sample size

493

Topic classification

Prediction，MRI

Keypoint

 Initial PSA value, biopsy GG ≥4, ≥rT3 disease on mpMRI and miN1 disease on PSMA PET were predictors of early biochemical progression after RARP. 

Year